PTSD Related News
How can a social networking app help MS patients?
Rehabilitation psychologist Dr Roy Aloni discusses MS-related distress and explains how an app can support MS patients experiencing this.
Multiple sclerosis (MS) is a condition...
Findings on stress could lead to treatments for PTSD and other conditions
New research has uncovered how key proteins interact to regulate the body’s response to stress – a finding that could lead to new treatments...
Clinical trial explores psychedelic treatments for PTSD in veterans
A company exploring the efficacy of psychedelic treatments for PTSD in veterans has announced the international expansion of its Phase 2A clinical trials.
The Mydecine...
The Ketamine Conference: A Molecular Masterclass
The Ketamine Conference: A Molecular Masterclass is set to take place today, featuring a host of experts in the delivery of ketamine therapy for...
Drug policy reform group urges Home Office to reschedule psilocybin
The Conservative Drug Policy Reform Group (CDPRG) has published a new report with the Adam Smith Institute outlining the potential medical benefits of psilocybin...
Mental Health Awareness Week: COVID-19 mental health research
Mental Health Awareness week takes place from 18 – 22 May, and, during the COVID-19 crisis ensuring good mental health is more important than...
Supporting the mental health of frontline NHS staff during COVID-19
Guidance has been issued to help support the mental health of frontline NHS staff during the COVID-19 pandemic.
An academic review has highlighted the increased...
Cannabis vaping devices reimbursement approval for Canadian veterans
Medical cannabis vaping devices have received reimbursement approval for Canadian veterans.
Signature By Liberty Leaf, a division of Liberty Leaf Holdings, has announced that it...
MDMA-assisted psychotherapy for PTSD approved by FDA
A new programme will enrol 50 PTSD patients for MDMA-assisted psychotherapy following FDA approval.
The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) was recently granted...
CMC calls on UK government to review medical cannabis policy
Today, the Centre for Medicinal Cannabis (CMC) is calling on the UK government to urgently review medical cannabis policy relating to cannabis access.
The call...
Why MDMA must be reclassified as a Schedule 2 drug
Amanda Feilding of the Beckley Foundation discusses the organisations new report ‘Roadmaps to Regulation: MDMA’ which recommends rescheduling MDMA to a Schedule 2 drug.
MDMA...
World’s first magic mushroom nasal spray for PTSD and depression
PTSD and depression are two conditions that are being trialled for treatment with psilocybin.
A ‘magic mushroom’ nasal spray has been designed to make microdosing...
Long-term use of opioids could increase risk of PTSD
Links have been drawn between long-term opioid use and increased risk of PTSD.
According to a study published in Neuropsychopharmacology, long-term treatment with opioids could...
Brain injuries and PTSD: injuries change how we process fear
A UCLA team of psychologists and neurologists reports that a traumatic brain injury causes changes in a brain region called the amygdala; and the...
Rare sleep disorder common among veterans with PTSD
Military veterans with post-traumatic stress disorder or concussion suffer from a thrashing form of sleep behaviour at a rate that is far higher than...
Cannabis may hold promise to treat PTSD but more research is needed
Since the legalisation of cannabis for medical use in America and a number of other countries, more and more people are turning to cannabis...
